Indications for: CLEVIPREX

To reduce blood pressure when oral therapy is not feasible or desirable.

Adult Dosage:

≥18yrs: Individualize; titrate. Give by IV infusion. Initially 1–2mg/hr; double dose at 90sec intervals until BP approaches goal, then titrate slower (adjust at 5–10min intervals). Dose increases of 1–2mg/hr results in systolic BP lowering of about 2–4mmHg. Maintenance: 4–6mg/hr; usual max 16–32mg/hr. Do not exceed 1000mL (21mg/hr for 24hrs) due to lipid load. Switch to oral therapy when indicated.

Children Dosage:

<18yrs: not established.

CLEVIPREX Contraindications:

Egg or soy allergy. Defective lipid metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia). Severe aortic stenosis.

CLEVIPREX Warnings/Precautions:

Maintain aseptic technique. Monitor BP and pulse during infusion and until stabilized. Heart failure (monitor). Monitor for rebound hypertension for at least 8hrs after stopping infusion (if not given other antihypertensives after prolonged infusion). Avoid abrupt cessation of any β-blocker treatment. Pheochromocytoma. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

CLEVIPREX Classification:

Calcium channel blocker (CCB) (dihydropyridine).

Adverse Reactions:

Headache, nausea, vomiting; hypotension, reflex tachycardia (slow infusion if occurs, do not use beta-blocker); rare: myocardial infarction, cardiac arrest, syncope, dyspnea.

Generic Drug Availability:


How Supplied:

Single-use vials (50mL, 100mL)—10